High Dose Ethinylestradiol for Advanced Breast Cancer
Author Information
Author(s): Amit Agrawal, John F. Robertson, K. L. Cheung
Primary Institution: University of Nottingham
Hypothesis
Can high dose ethinylestradiol be an effective treatment for post-menopausal women with advanced breast cancer who have been heavily pre-treated with endocrine agents?
Conclusion
High dose ethinylestradiol is a viable treatment option for heavily pre-treated advanced breast cancer patients, despite potential side effects.
Supporting Evidence
- 33.3% of patients showed clinical benefit from ethinylestradiol treatment.
- The median duration of response was over 10 months.
- One patient experienced severe side effects leading to early withdrawal from treatment.
Takeaway
This study looked at whether a medicine called ethinylestradiol could help women with advanced breast cancer who had already tried many other treatments. It found that it worked for some of them.
Methodology
Patients were treated with ethinylestradiol (1 mg daily) until they experienced adverse events or disease progression.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study had a small sample size and was retrospective in nature.
Participant Demographics
All participants were post-menopausal women with advanced breast cancer, median age 75.1 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website